Abstract 638P
Background
Stereotactic ablative radiotherapy (SABR) has been shown to sensitize immunotherapy through inducing immunogenic death and remodeling the tumor immune microenvironment. Anti-angiogenic therapy exhibits synergistic antitumor effects with PD-1/PD-L1 antibodies through its immunomodulatory effects for ≥ 3L metastatic colorectal cancer (mCRC) patients. Here, we report the preliminary results from RIFLE trial: the efficacy and safety of the combination of fruquintinib, PD-1 inhibitor tislelizumab and SABR in mCRC patients.
Methods
This is a single-center, single-arm, prospective phase II clinical trial (NCT04948034). mCRC patients with at least 2 measurable lesions who have failed ≥ 1L standard therapy will receive SABR followed by fruquintinib (5 mg, d1-14, qd) and tislelizumab (200 mg, d1, q3w) within two weeks from completion of radiation. The primary endpoint is the objective response rate (ORR). The secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate and toxicity.
Results
From August 2021 to April 2023, 27 patients were included in the trial and 24 in the efficacy analysis. Median age was 64 years, 17 (70.8%) patients were male, 21(87.5%) had ≥ 3 metastases, and 12(50%) had received ≥ 3 prior lines of systemic therapy. The biological effective dose (BED) for irradiated lesions ranged from 37.5 to 105 Gy. Median study follow-up was 12.6 months, 20 patients were alive and 11 remained on treatment. 7 patients achieved partial response (PR) for target lesions, 10 stable disease (SD), illustrating an ORR of 29.2% and a DCR of 70.8%. Median PFS was not reached. The most common treatment-related adverse events (TRAEs) were proteinuria (45.8%), hypertension (25%) and rash (16.7%). Grade 3-4 AEs occurred in 8 patients, including proteinuria and hypertension, and there were no treatment-related deaths.
Conclusions
SABR combined with tislelizumab and fruquintinib shows promising effects and good safety in the treatment of metastatic colorectal cancer, which is expected to provide new therapeutic strategies and improve the prognosis for mCRC patients.
Clinical trial identification
NCT04948034.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Hutchison MediPharma Co., Ltd. and BeiGene (Beijing) Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11